ImmunoWork is aiming to deliver a cure for primary membranous nephropathy (PMN), an autoimmune kidney disease. The challenge for PMN treatment is the frequent relapse of the disease after its clinical remission, which leads to kidney failure in ~ 5-10 years. Once this occurs, patients have no choice but to rely their lives on dialysis and kidney transplant.
There are ~4000 and ~10,000 new PMN cases in North America and Europe each year. In China, PMN has become the first leading cause of glomerulonephritis exceeded the frequency of any other glomerular diseases. The total new cases of PMN across the globe are estimated to be over 80,000 per year, and the market size is estimated to be over 1.2 billion.
ImmunoWork has developed a new technology to specifically target the autoantibody producing immune cells that will result in a life-long cure for PMN patients. This new treatment is specific and effective with minimal side effects. There is no similar technology currently available on market.
ImmunoWork developed and owns the exclusive rights of the intellectual property assets include a U.S. patent application, know-how, and trade secrets. The patent application claims cover broad aspects of the scientific and clinical use of the products, present and future.